CD4 and metastatic melanoma: In this regard, in a study of patients with irresectable and/or metastatic melanoma (MM) (n = 43) and NSCLC (n = 40) treated with nivolumab [35], tumors with increased inflammatory gene transcripts had increased ratios of CD4+ and CD8+ Tcm cells to Teff in the blood.